Early bird registration is open and closes May 2025. Register now
Abstracts deadline EXTENDED Friday 22 May 2026! Submit now
More information coming soon. Agenda – Thursday 29 October Workshop chairperson: Kichul Shin 1330-1440 Presentation title TBC Xenofon Baraliakos 1440-1455 Presentation title TBC Mitsumasa Kishimoto
Crossroads of Inflammation: What Advances in PsA/SpA Mean for Clinical Practice Objectives: The APEX study evaluated guselkumab in adults with active, erosive psoriatic arthritis and demonstrated meaningful clinical and radiographic benefits through Week 48. Participants met predefined activity and erosive criteria and were randomized to two guselkumab dosing regimens or placebo with crossover at Week 24. By Week 48, both guselkumab schedules showed sustained improvements in ACR20 and ACR50 responses, along with continued suppression of radiographic progression, while patients switched
Title coming soon Objectives: Agenda: Chairperson:Jose Paulo Lorenzo
Tacrolimus strategy for Autoimmune real-world in Rheumatic Disease Objectives: Agenda: Speakers:Jihyun Kang
The significance of IL-6 signal blocking in autoimmune diseases including RA Objectives: Information coming soon. Agenda – Wednesday 30 October Workshop chairpersons: Tsutomu Takeuchi and Sang-heon Lee TBC Presentation title TBC Chan-bum Choi TBC Presentation title TBC Ryu Watanabe
Shifting the Trajectory: Understanding the Implications of an early subcutaneous application of Methotrexate Early use of subcutaneous methotrexate MTX can shift the treatment trajectory by improving disease control, reducing side effects, and delaying other therapies. It is particularly valuable for patients with oral intolerance or inadequate response to oral MTX. Therefore subcutaneous MTX plays an increasingly important role in the treatment of rheumatoid arthritis (RA) because it offers clinical advantages compared to oral use: Greater Clinical EfficacyStudies show that patients
Norway was one of the first countries to implement widespread biosimilar use, led by pioneering research such as the NOR-SWITCH study. This session features Professor Tore K. Kvien, who will share his extensive, decade-long experience with biosimilars in clinical practice. The discussion will move beyond theoretical benefits to focus on long-term real-world data, the evolution of clinician and patient perspectives, and the practical “Experience” that has shaped current rheumatology standards. This is a unique opportunity to learn from the definitive
Have you submitted your abstract yet?
Don't miss your chance on being part of APLAR 2026 where live sessions feature the latest, best-in-class research and provide an opportunity to connect and stay apprised of the latest developments and innovations in the field.
